To provide the information your oncologist is not telling you or doesn't have the time to!
In a groundbreaking move, the Food and Drug Administration (FDA) has granted approval for enzalutamide (Xtandi, Astellas Pharma US, Inc.) to address non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence. This significant development brings renewed hope for patients at high risk for metastasis. The Road to Approval: EMBARK Trial Insights In the EMBARK clinical trial …
This post is dedicated to all the hard working oncology nurses! In cancer care, oncology nurses are often the unsung heroes, playing a myriad of roles that go beyond traditional nursing responsibilities. This post celebrates these compassionate caregivers, shedding light on the multifaceted roles they play in the journey of a cancer patient. 1. Patient …
Cancer screening has witnessed a transformative evolution, with technological advancements paving the way for more effective and less invasive methods. In this article, we will explore the integration of liquid biopsies as a groundbreaking approach to early cancer detection. This non-invasive method holds immense potential in detecting genetic alterations and circulating tumor DNA, ushering in …
In a groundbreaking development for patients with progressing desmoid tumors, the Food and Drug Administration (FDA) has granted approval for nirogacestat, a novel treatment provided by SpringWorks Therapeutics, Inc. This approval marks a significant milestone as the first-ever sanctioned therapy for desmoid tumors, offering hope and a new avenue of treatment for affected individuals. Let’s …
In the realm of oncology, antibiotics assume a nuanced, yet critical role. They stand as guardians against bacterial threats, but wield a double-edged sword when it comes to their interaction with cancer treatments and the patient’s microbiome. This piece aims to untangle the complexities of antibiotic use in cancer care, highlighting how they operate, when …
The latest development in breast cancer treatment brings hope and progress. On November 16, 2023, the Food and Drug Administration (FDA) approved capivasertib, in combination with fulvestrant, for adult patients battling hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. This approval marks a significant step forward for …
This is a new modified TIL protocol developed by Obsidian Therapeutics now open for enrollment at the Orlando Health Cancer Institute. All information provided here are from public sources and the protocol details can be found here. Please reach out to Karin Donaldson if interest in seeking this trial. This current protocol is specific for …
Pancreatic cancer is a highly aggressive form of cancer that often goes undetected until it reaches an advanced stage. To improve treatment outcomes, individuals must be aware of the early warning signs and seek medical attention promptly. This article aims to educate readers about the signs and symptoms of pancreatic cancer, emphasizing the importance of …
Living with neuroendocrine cancer can present a range of physical, emotional, and social challenges. However, with the right mindset and support, individuals can effectively manage symptoms and enhance their quality of life. Today we provide practical tips for handling common symptoms such as flushing, diarrhea, fatigue, and anxiety. Additionally, it highlights the role of supportive …
by Sajeve Thomas, MD, Oncologist Biliary tract cancer (BTC), a rare and aggressive form of cancer affecting the bile ducts, gallbladder, and liver, has historically been challenging to treat. However, there is hope on the horizon with the recent FDA approval of pembrolizumab (Keytruda, Merck) in combination with chemotherapy. This groundbreaking development offers new possibilities …